Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SI | P14410 | 3/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601827 | 0.83 | QPCT (0.58) | QPCTQPCTLKDM4EALDH1A1MAPT | |
| SCHEMBL1601334 | 0.74 | QPCT (1.00) | QPCTQPCTLKDM4EALDH1A1MAPT | |
| SCHEMBL759126 | 0.71 | NOS1 (0.50) | KDM4EALDH1A1MAPTGAAADORA2A | |
| SCHEMBL20667602 | 0.71 | ADORA2A (0.42) | QPCTQPCTLADORA2A | |
| SCHEMBL1601205 | 0.70 | AKT1 (0.75) | — | |
| SCHEMBL1601203 | 0.70 | AKT1 (0.75) | — | |
| SCHEMBL25167318 | 0.70 | ADORA2A (0.51) | ADORA2ANOS1 | |
| SCHEMBL11331186 | 0.69 | KDM4E (0.66) | KDM4EALDH1A1MAPTL3MBTL1MGAM | |
| SCHEMBL22230382 | 0.69 | ADORA2A (0.62) | MAPTADORA2ANOS1 | |
| SCHEMBL31690852 | 0.69 | ADORA2A (0.50) | ADORA2ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809282-B1 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7919514-B2 | Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| CN-101389335-A | Thiadiazole compounds and methods of use. | AMGEN INC (US) | 2009-03-18 | — | — | CN | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | QPCT 2416/4885QPCTL 4190/4885KDM4E 3312/4885 |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | SGK2, SGK1, SGK3 | QPCT 3506/4885QPCTL 3770/4885KDM4E 1911/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | QPCT 2416/4885QPCTL 4190/4885KDM4E 3312/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | QPCT 2416/4885QPCTL 4190/4885KDM4E 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.